Private equity shops thought they saw a sure-fire way to make a buck: build dozens of new power plants fueled by cheap Appalachian natural gas to replace old coal-fired units.
It hasn’t quite turned out that way, at least not yet. Many of the new plants built in the last few years aren’t kicking off as much cash as the buyout firms had expected, according to bankers. There’s not enough demand to support the huge amount of additional new capacity, driving down electricity prices. And with President Donald Trump as a booster, shutdowns of coal haven’t come as quickly as anticipated while states are acting to keep nuclear plants open.
None of the new plants appear in danger of default, analysts said. But several plant owners are now using most of the extra cash they are generating to pay down debt.
Moreover, low prices and the results of a closely watched regional power-price auction scheduled for Wednesday could force many of the gas-fired plants built in the last five years to refinance their debt. At least one new U.S. plant, owned in part by an arm of private equity firm Ares Management LP, recently did so.
Top Low Price Stocks To Own Right Now: Celldex Therapeutics Inc(CLDX)
Advisors' Opinion:- [By Motley Fool Staff]
Celldex (NASDAQ:CLDX) has unveiled thoroughly disappointing results for its lead drug, glembatumumab vedotin (glemba), that casts doubt on its future. Can the company bounce back from this failure?
- [By Keith Speights]
If you like putting money into the beaten-down stocks of clinical-stage biotechs, Ziopharm Oncology (NASDAQ:ZIOP) and Celldex Therapeutics (NASDAQ:CLDX) might warrant a look. Ziopharm's share price has dropped more than 25% so far in 2018, while Celldex stock has plunged more than 80%.
- [By George Budwell]
Shares of Celldex Therapeutics (NASDAQ:CLDX), a small-cap cancer company, are down by over 43% in pre-market trading today on extremely heavy volume. What's going on?
- [By Paul Ausick]
Celldex Therapeutics Inc. (NASDAQ: CLDX) dropped about 1.6% Wednesday to post a new 52-week low of $0.62. Shares closed at $0.63 on Tuesday and the stock’s 52-week high is $3.26. Volume of around 3.1 million shares was roughly equal to the daily average.The company had no specific news.
- [By Paul Ausick]
Celldex Therapeutics Inc. (NASDAQ: CLDX) fell about 3.4% Thursday to post a new 52-week low of $0.56. Shares closed at $0.58 on Wednesday. The 52-week high is $3.26. Volume of around 3.5 million was about equal to the daily average. The company had no specific news.
Top Low Price Stocks To Own Right Now: La-Z-Boy Incorporated(LZB)
Advisors' Opinion:- [By Steve Symington]
Shares of La-Z-Boy Incorporated (NYSE:LZB) were up 12.6% as of 1:30 p.m. EDT on Wednesday after the furniture producer announced strong fiscal first-quarter 2019 results.
- [By Joseph Griffin]
Get a free copy of the Zacks research report on La-Z-Boy (LZB)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Joseph Griffin]
Get a free copy of the Zacks research report on La-Z-Boy (LZB)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Logan Wallace]
Get a free copy of the Zacks research report on La-Z-Boy (LZB)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Dan Caplinger]
Thursday was another relatively calm day on Wall Street, with most major benchmarks easing very slightly lower. Fears about Washington scandals and trade tensions between the U.S. and China weighed on enthusiasm over a strong U.S. economy as economists and policymakers met in Jackson Hole, Wyoming, for the Federal Reserve's annual symposium to discuss economic prospects across the globe. At a more granular level, some companies suffered from downbeat news that sent their share prices lower. IAMGOLD (NYSE:IAG), Hertz Global Holdings (NYSE:HTZ), and La-Z-Boy (NYSE:LZB) were among the worst performers on the day. Here's why they did so poorly.
- [By Shane Hupp]
Get a free copy of the Zacks research report on La-Z-Boy (LZB)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Top Low Price Stocks To Own Right Now: Hingham Institution for Savings(HIFS)
Advisors' Opinion:- [By Max Byerly]
Port Capital LLC lifted its stake in Hingham Institution for Savings (NASDAQ:HIFS) by 14.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 48,159 shares of the savings and loans company’s stock after purchasing an additional 5,943 shares during the quarter. Hingham Institution for Savings accounts for approximately 1.4% of Port Capital LLC’s holdings, making the stock its 25th biggest position. Port Capital LLC owned approximately 2.28% of Hingham Institution for Savings worth $9,921,000 at the end of the most recent reporting period.
- [By Joseph Griffin]
Epoch Investment Partners Inc. grew its stake in Hingham Institution for Savings (NASDAQ:HIFS) by 71.4% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 92,261 shares of the savings and loans company’s stock after purchasing an additional 38,440 shares during the quarter. Epoch Investment Partners Inc. owned approximately 4.37% of Hingham Institution for Savings worth $19,006,000 as of its most recent SEC filing.
- [By Ethan Ryder]
Hingham Institution for Savings (NASDAQ:HIFS) and SVB Financial Group (NASDAQ:SIVB) are both finance companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, earnings, analyst recommendations and dividends.
Top Low Price Stocks To Own Right Now: ABAXIS Inc.(ABAX)
Advisors' Opinion:- [By Max Byerly]
Tiedemann Advisors LLC bought a new position in shares of Abaxis (NASDAQ:ABAX) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 3,000 shares of the medical research company’s stock, valued at approximately $213,000.
- [By Logan Wallace]
TRADEMARK VIOLATION NOTICE: “Brokerages Expect Abaxis (ABAX) Will Post Earnings of $0.32 Per Share” was posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be read at https://www.tickerreport.com/banking-finance/3373644/brokerages-expect-abaxis-abax-will-post-earnings-of-0-32-per-share.html.
- [By Ethan Ryder]
Get a free copy of the Zacks research report on Abaxis (ABAX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Lisa Levin]
Abaxis, Inc. (NASDAQ: ABAX) shares were also up, gaining 15 percent to $82.75. Zoetis Inc. (NYSE: ZTS) announced plans to acquire Abaxis for $83 per share in cash.
Top Low Price Stocks To Own Right Now: Northwest Biotherapeutics, Inc.(NWBO)
Advisors' Opinion:- [By ]
Northwest Biotherapeutics (OTC:NWBO) presented underwhelming preliminary data from a late-stage study of DCVax-L in brain cancer.
Community Health Systems (NYSE:CYH) amended to extend the "Early Tender Deadline" and the "Expiration Date" for each Exchange Offer announced earlier.
- [By ]
The last time we left Northwest Biotherapeutics (OTC:NWBO), I stated in a fairly cautious article that there are persistent risks associated with an investment in this company. Back in November, I did not feel that the benefits outweighed the risks for this small cap equity.
Top Low Price Stocks To Own Right Now: CUI Global, Inc.(CUI)
Advisors' Opinion:- [By Ethan Ryder]
TESSCO Technologies (NASDAQ: TESS) and CUI Global (NASDAQ:CUI) are both small-cap computer and technology companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk.
No comments:
Post a Comment